Community-Acquired Pneumonia Treatment Guidelines

Introduction to CAP Treatment

The American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) strongly recommend amoxicillin as first-line therapy for healthy adults without comorbidities, based on moderate quality evidence 1, 2
For adults with comorbidities, the ATS/IDSA guidelines recommend either combination therapy with a beta-lactam plus a macrolide or monotherapy with a respiratory fluoroquinolone 1, 2

Amoxicillin 1g three times daily is recommended as first-line therapy for healthy adults without comorbidities, with a strong recommendation and moderate quality evidence 1, 2, 3
Doxycycline 100mg twice daily is conditionally recommended for healthy adults without comorbidities, with low quality evidence 1, 2
Macrolides, such as azithromycin or clarithromycin, may be used as monotherapy in areas with low pneumococcal resistance (<25%), with a conditional recommendation and low quality evidence 1, 2

Combination therapy with a beta-lactam (such as amoxicillin-clavulanate) plus a macrolide (such as azithromycin or clarithromycin) is recommended for adults with comorbidities, with a strong recommendation and moderate quality evidence 1, 2, 4
Monotherapy with a respiratory fluoroquinolone (such as levofloxacin or moxifloxacin) is also recommended for adults with comorbidities, with a strong recommendation and moderate quality evidence 1, 2, 4

Local resistance patterns should be considered when selecting therapy, and macrolide monotherapy should be avoided in areas with high pneumococcal resistance (>25%) 1, 2
Recent antibiotic use should be taken into account, and an alternative from a different class should be selected to reduce the risk of resistance 4
Fluoroquinolones should be used judiciously due to higher rates of adverse events and risk of promoting resistance 4
Treatment failure should be reassessed and considered for hospitalization if clinical improvement is not observed within 48-72 hours 1, 2